Related Experiment Video
Updated: May 4, 2026
08:59
Human Subcutaneous Adipose Tissue Sampling Using a Mini-Liposuction Technique
Published on: September 27, 2021
3.4K
Practice guidelines for the use of subcutaneous abatacept
Emilio Martín Mola1, Alejandro Balsa1, Víctor Martínez Taboada2
1Servicio de Reumatología, Hospital Universitario La Paz, IdiPAZ, Madrid, España.
Reumatologia Clinica
|January 7, 2014
Summary
Subcutaneous (sc) abatacept demonstrates comparable efficacy and safety to intravenous (iv) abatacept for rheumatoid arthritis (RA) treatment. This review provides practical recommendations for its use in rheumatology, highlighting its versatility.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) management involves various biologic agents.
- Subcutaneous (sc) abatacept offers an alternative administration route to intravenous (iv) abatacept.
- Understanding the clinical evidence for sc abatacept is crucial for optimizing RA treatment.
Purpose of the Study:
- To review clinical evidence for subcutaneous (sc) abatacept.
- To provide recommendations for its use in rheumatology.
- To clarify points regarding sc abatacept administration and effectiveness.
Main Methods:
- Expert panel of rheumatologists conducted a literature review.
- Evidence on mechanism of action, practicality, effectiveness, and safety was summarized.
- Recommendations were formulated based on the evidence synthesis.
Main Results:
- Seven clinical trials evaluated efficacy and safety of sc abatacept.
- No significant differences in efficacy or safety were observed between sc and iv abatacept.
- Sc abatacept showed non-inferiority to adalimumab and effectiveness in monotherapy.
Conclusions:
- Subcutaneous abatacept is an effective and safe treatment option for RA.
- It serves as a valuable alternative within the rheumatologist's armamentarium.
- Its dual iv and sc administration offers flexibility for patient use.
